Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEA115661: Long-term open-label safety study of mepolizumab in severe asthma
2012-001644-21Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in asthma, sponsored by GSK. Primary endpoint: Adverse events. Started Jan 2013; status: completed.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2012-001644-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001644-21.